{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:58:07Z","timestamp":1770843487340,"version":"3.50.1"},"reference-count":103,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T00:00:00Z","timestamp":1385596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0077756","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T21:05:05Z","timestamp":1385672705000},"page":"e77756","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Detection of HIV-1 Neutralizing Antibodies in a Human CD4+\/CXCR4+\/CCR5+ T-Lymphoblastoid Cell Assay System"],"prefix":"10.1371","volume":"8","author":[{"given":"Robert J.","family":"McLinden","sequence":"first","affiliation":[]},{"given":"Celia C.","family":"LaBranche","sequence":"additional","affiliation":[]},{"given":"Agn\u00e8s-Laurence","family":"Chenine","sequence":"additional","affiliation":[]},{"given":"Victoria R.","family":"Polonis","sequence":"additional","affiliation":[]},{"given":"Michael A.","family":"Eller","sequence":"additional","affiliation":[]},{"given":"Lindsay","family":"Wieczorek","sequence":"additional","affiliation":[]},{"given":"Christina","family":"Ochsenbauer","sequence":"additional","affiliation":[]},{"given":"John C.","family":"Kappes","sequence":"additional","affiliation":[]},{"given":"Stephen","family":"Perfetto","sequence":"additional","affiliation":[]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[]},{"given":"Nelson L.","family":"Michael","sequence":"additional","affiliation":[]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2013,11,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","article-title":"Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials","volume":"206","author":"DC Montefiori","year":"2012","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/422258","article-title":"Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults","volume":"190","author":"S Nitayaphan","year":"2004","journal-title":"J Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-030409-101256","article-title":"The role of antibodies in HIV vaccines","volume":"28","author":"JR Mascola","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine","volume":"455","author":"DH Barouch","year":"2008","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by pasive infusion of neutralizing antibodies","volume":"6","author":"JR Mascola","year":"2000","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1128\/JVI.75.17.8340-8347.2001","article-title":"Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro","volume":"75","author":"PW Parren","year":"2001","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection","volume":"6","author":"TW Baba","year":"2000","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/00002030-199411000-00017","article-title":"HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals","volume":"8","author":"T Wrin","year":"1994","journal-title":"AIDS"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/173.2.340","article-title":"Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group","volume":"173","author":"JR Mascola","year":"1996","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-199818000-00009","article-title":"Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers","volume":"12","author":"RB Belshe","year":"1998","journal-title":"AIDS"},{"key":"ref13","article-title":"Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by soluble gp160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. Manuscript submitted","author":"R Bures","year":"2000"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.virol.2008.02.007","article-title":"Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination","volume":"375","author":"VR Polonis","year":"2008","journal-title":"Virology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"L Qin","year":"2007","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"SA Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/QAD.0b013e32832e9408","article-title":"HIV sensitivity to neutralization is determined by target and virus producer cell properties","volume":"23","author":"AM Mann","year":"2009","journal-title":"AIDS"},{"key":"ref18","first-page":"309","article-title":"Neutralization of HIV-1 infection of human peripheral blood mononuclear cells (PBMC): antibody dilution method","year":"1999"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e4505","DOI":"10.1371\/journal.pone.0004505","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report","volume":"4","author":"EM Feny\u00f6","year":"2009","journal-title":"PLOS ONE"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"10103","DOI":"10.1128\/JVI.79.16.10103-10107.2005","article-title":"Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines","volume":"79","author":"JR Mascola","year":"2005","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"18514","DOI":"10.1073\/pnas.0504658102","article-title":"Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection","volume":"102","author":"SD Frost","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"DD Richman","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"X Wei","year":"2003","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/1096-9071(200009)62:1<14::AID-JMV3>3.0.CO;2-L","article-title":"Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates","volume":"62","author":"E Beirnaert","year":"2000","journal-title":"J Med Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1128\/JVI.01482-09","article-title":"Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables","volume":"84","author":"NA Doria-Rose","year":"2010","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"MD Simek","year":"2009","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm.1949","article-title":"Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?","volume":"15","author":"L Stamatatos","year":"2009","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1128\/JVI.78.23.13232-13252.2004","article-title":"Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies","volume":"78","author":"JM Binley","year":"2004","journal-title":"J Virol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"LM Walker","year":"2009","journal-title":"Science"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1128\/JVI.00033-08","article-title":"Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens","volume":"82","author":"MY Zhang","year":"2008","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e8805","DOI":"10.1371\/journal.pone.0008805","article-title":"Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals","volume":"5","author":"D Corti","year":"2010","journal-title":"PLOS ONE"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"LM Walker","year":"2011","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"X Wu","year":"2011","journal-title":"Science"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"JF Scheid","year":"2011","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/JVI.01839-06","article-title":"Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection","volume":"81","author":"R Rong","year":"2007","journal-title":"J Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/JVI.02006-10","article-title":"The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter","volume":"85","author":"RM Lynch","year":"2011","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/JVI.02187-07","article-title":"The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection","volume":"82","author":"PL Moore","year":"2008","journal-title":"J Virol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/COH.0b013e32832ea7e8","article-title":"Specificity of the autologous neutralizing antibody response","volume":"4","author":"PL Moore","year":"2009","journal-title":"Curr Opin HIV AIDS"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e1000598","DOI":"10.1371\/journal.ppat.1000598","article-title":"Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection","volume":"5","author":"PL Moore","year":"2009","journal-title":"PLoS Pathog"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1128\/JVI.00257-07","article-title":"Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1","volume":"81","author":"R Rong","year":"2007","journal-title":"J Virol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e1000594","DOI":"10.1371\/journal.ppat.1000594","article-title":"Escape from autologous neutralizing antibodies in acute\/early subtype C HIV-1 infection requires multiple pathways","volume":"5","author":"R Rong","year":"2009","journal-title":"PLoS Pathog"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"9286","DOI":"10.1128\/JVI.02286-10","article-title":"epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals","volume":"85","author":"H Tang","year":"2011","journal-title":"J Virol"},{"key":"ref44","article-title":"Profiling the Specificity of Neutralizing Antibodies in a Large Panel of HIV-1 Plasmas from Subtype B and C Chronic Infections","author":"JM Binley","year":"2008","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1128\/JVI.02749-06","article-title":"Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors","volume":"81","author":"AK Dhillon","year":"2007","journal-title":"J Virol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.1128\/JVI.00758-09","article-title":"Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors","volume":"83","author":"ES Gray","year":"2009","journal-title":"J Virol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies","volume":"13","author":"Y Li","year":"2007","journal-title":"Nat Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/JVI.01992-08","article-title":"Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals","volume":"83","author":"Y Li","year":"2009","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JVI.02036-08","article-title":"Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection","volume":"83","author":"DN Sather","year":"2009","journal-title":"J Virol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1128\/JVI.05363-11","article-title":"Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals","volume":"85","author":"GD Tomaras","year":"2011","journal-title":"J Virol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"X Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bbrc.2006.07.163","article-title":"Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration","volume":"348","author":"V Choudhry","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/JVI.02011-06","article-title":"Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites","volume":"81","author":"BK Brown","year":"2007","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.virol.2008.02.022","article-title":"Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models","volume":"375","author":"BK Brown","year":"2008","journal-title":"Virology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1086\/654816","article-title":"Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine","volume":"202","author":"P Gilbert","year":"2010","journal-title":"J Infect Dis"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.1016\/S0021-9258(19)50353-2","article-title":"Complete replacement of membrane cholesterol with 4,4&apos;,14-trimethyl sterols in a human T cell line defective in lanosterol demethylation","volume":"267","author":"TM Buttke","year":"1992","journal-title":"J Biol Chem"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1073\/pnas.82.13.4539","article-title":"Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus","volume":"82","author":"T Folks","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1097-0320(19981001)33:2<133::AID-CYTO7>3.0.CO;2-K","article-title":"CD38 expression on cryopreserved CD8+ T cells predicts HIV disease progression","volume":"33","author":"SP Perfetto","year":"1998","journal-title":"Cytometry"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.4049\/jimmunol.133.4.1857","article-title":"Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen","volume":"133","author":"AI Lazarovits","year":"1984","journal-title":"J Immunol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"CA Derdeyn","year":"2000","journal-title":"J Virol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"EJ Platt","year":"1998","journal-title":"J Virol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/viro.2000.0780","article-title":"A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1","volume":"280","author":"C Spenlehauer","year":"2001","journal-title":"Virology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1128\/JVI.73.11.8966-8974.1999","article-title":"A cell line based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor","volume":"73","author":"A Trkola","year":"1999","journal-title":"J Virol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/JVI.75.8.3903-3915.2001","article-title":"Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4","volume":"75","author":"RE Means","year":"2001","journal-title":"J Virol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-3-20","article-title":"Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and &quot;RecycleSpot&quot;","volume":"3","author":"FK Bihl","year":"2005","journal-title":"J Transl Med"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1084\/jem.20070695","article-title":"Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR\/HLA subtypes","volume":"204","author":"G Alter","year":"2007","journal-title":"J Exp Med"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1097-0320(20000601)40:2<141::AID-CYTO8>3.0.CO;2-F","article-title":"A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates","volume":"40","author":"JM Darden","year":"2000","journal-title":"Cytometry"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088922201750056807","article-title":"HIV type 1 subtype E-infected patients with broadened, dual (B\/E) V3 loop serology have increased cross-neutralizing antibodies","volume":"17","author":"VR Polonis","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/JCM.37.8.2557-2563.1999","article-title":"Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes","volume":"37","author":"NL Michael","year":"1999","journal-title":"J Clin Microbiol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/infdis\/169.1.48","article-title":"Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype","volume":"169","author":"JR Mascola","year":"1994","journal-title":"J Infect Dis"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2010.08.028","article-title":"Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC","volume":"408","author":"TG Edmonds","year":"2010","journal-title":"Virology"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1128\/JVI.06157-11","article-title":"Generation of transmitted\/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages","volume":"86","author":"C Ochsenbauer","year":"2012","journal-title":"J Virol"},{"key":"ref73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076104","article-title":"Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone. PLoS ONE. Manuscript accepted","author":"AL Chenine","year":"2013"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies","volume":"79","author":"M Li","year":"2005","journal-title":"J Virol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1089\/088922203769232601","article-title":"Specific antibody responses to vaccination with bivalent CM235\/SF2 gp120: detection of homologous and heterologous neutralizing antibody (NAb) to subtype E HIV-1","volume":"19","author":"JH Kim","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/QAI.0b013e3181354bd7","article-title":"A phase 1\/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023\/LAI-DID) or bivalent gp120 (CM235\/SF2) boost","volume":"46","author":"P Thongcharoen","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ni1566","article-title":"HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells","volume":"9","author":"J Arthos","year":"2008","journal-title":"Nat Immunol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1073\/pnas.91.8.3348","article-title":"Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody","volume":"91","author":"AJ Conley","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref79","article-title":"Neutralization of the human immunodeficiency virus type 1 primary isolate","author":"TR Fouts","year":"1997"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1128\/JVI.71.10.7198-7206.1997","article-title":"Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12","volume":"71","author":"JR Mascola","year":"1997","journal-title":"J Virol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.1128\/JVI.75.22.10892-10905.2001","article-title":"Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41","volume":"75","author":"MB Zwick","year":"2001","journal-title":"J Virol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1128\/JVI.69.11.6609-6617.1995","article-title":"Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG","volume":"69","author":"A Trkola","year":"1995","journal-title":"J Virol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e32832faea5","article-title":"Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes","volume":"23","author":"GR Matyas","year":"2009","journal-title":"AIDS"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/vim.2010.0061","article-title":"The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization","volume":"23","author":"KK Peachman","year":"2010","journal-title":"Viral Immunol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/509259","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine","volume":"194","author":"BS Graham","year":"2006","journal-title":"J Infect Dis"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.vaccine.2007.12.024","article-title":"Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers","volume":"26","author":"S Wang","year":"2008","journal-title":"Vaccine"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1086\/376506","article-title":"Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults","volume":"188","author":"P Pitisuttithum","year":"2003","journal-title":"J Infect Dis"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.virol.2005.06.003","article-title":"HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity","volume":"339","author":"MK Louder","year":"2005","journal-title":"Virology"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/QAD.0b013e32832d92c2","article-title":"Divergent effects of cell environment on HIV entry inhibitor activity","volume":"23","author":"P Rusert","year":"2009","journal-title":"AIDS"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/QAD.0b013e3282f3ca57","article-title":"Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope","volume":"22","author":"SW Barnett","year":"2008","journal-title":"AIDS"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"81ra36","DOI":"10.1126\/scitranslmed.3002351","article-title":"Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys","volume":"3","author":"NL Letvin","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"DH Barouch","year":"2012","journal-title":"Nature"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev.med.60.042507.164323","article-title":"Toward an antibody-based HIV-1 vaccine","volume":"61","author":"JA Hoxie","year":"2010","journal-title":"Annu Rev Med"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"20877","DOI":"10.1073\/pnas.0911796106","article-title":"The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1","volume":"106","author":"C Cicala","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"e1001301","DOI":"10.1371\/journal.ppat.1001301","article-title":"The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +\/CD4+ T cells as key targets in mucosal transmission","volume":"7","author":"F Nawaz","year":"2011","journal-title":"PLOS Pathog"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0966-842X(99)01474-2","article-title":"HIV-1 attachment: another look","volume":"7","author":"S Ugolini","year":"1999","journal-title":"Trends Microbiol"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1128\/JVI.00656-09","article-title":"Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41","volume":"83","author":"LG Perez","year":"2009","journal-title":"J Virol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1128\/JVI.00925-09","article-title":"Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection","volume":"83","author":"B Etemad","year":"2009","journal-title":"J Virol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1084\/jem.20091281","article-title":"Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines","volume":"207","author":"MA Moody","year":"2010","journal-title":"J Exp Med"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/rmv.367","article-title":"Potential roles of cellular proteins in HIV-1","volume":"12","author":"DE Ott","year":"2002","journal-title":"Rev Med Virol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1128\/JVI.71.6.4847-4851.1997","article-title":"Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization","volume":"71","author":"CD Rizzuto","year":"1997","journal-title":"J Virol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2009.02.046","article-title":"HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes","volume":"137","author":"K Miyauchi","year":"2009","journal-title":"Cell"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"P Pitisuttithum","year":"2006","journal-title":"J Infect Dis"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0077756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T13:59:14Z","timestamp":1688824754000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0077756"}},"subtitle":[],"editor":[{"given":"Yuntao","family":"Wu","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2013,11,28]]},"references-count":103,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0077756","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,28]]}}}